Postnatal use of corticosteroids in bronchopulmonary dysplasia
- Ann R Stark, MD
Ann R Stark, MD
- Professor of Pediatrics
- Vanderbilt University School of Medicine
- Eric C Eichenwald, MD
Eric C Eichenwald, MD
- Professor of Pediatrics
- Perelman School of Medicine, University of Pennsylvania
Clinical trials have shown that postnatal corticosteroid therapy administered systemically improves short-term lung function and outcome of infants with established bronchopulmonary dysplasia (BPD), and reduces the risk of BPD in high-risk preterm infants. However, systemic corticosteroid administration (primarily dexamethasone) is associated with serious adverse effects. As a result, currently available evidence suggests that the potential benefits of routine administration of postnatal corticosteroids are outweighed by its short- and long-term complications. (See "Pathogenesis and clinical features of bronchopulmonary dysplasia", section on 'Epidemiology'.)
The use of postnatal corticosteroid therapy, including its complications in preterm infants for prevention or treatment BPD, will be reviewed here. The overall prevention and treatment of BPD are discussed separately. (See "Prevention of bronchopulmonary dysplasia" and "Management of bronchopulmonary dysplasia".)
Postnatal corticosteroid administration is an area of intense clinical interest because of the desire to reduce the incidence and severity of bronchopulmonary dysplasia (BPD) (table 1). Despite numerous studies, however, it remains difficult to determine if a subset of infants exists in which the benefits of postnatal corticosteroid therapy outweigh its risks, due in part to difficulties in interpreting the data because of numerous methodologic issues.
These issues include variations in the preparation of corticosteroid used, the dosing and timing of administration, length of therapy, and the open label use of corticosteroids in patients in control groups, as well as limited data on long-term neurodevelopmental outcome. Open label use is defined as the use of prescribed corticosteroids by clinicians, in addition to the administration of the masked study drug. As a result, patients in the placebo group sometimes received corticosteroids, thereby minimizing differences between treatment and control groups. Because of these issues, the postnatal use of either systemic or inhaled corticosteroids in bronchopulmonary dysplasia is a controversial and continuously evolving subject.
Efficacy — Numerous clinical trials have shown the beneficial pulmonary effects of postnatal systemic corticosteroids in preterm infants. Two meta-analyses have divided these trials based upon the timing of administration and their focus on either prevention or treatment of established bronchopulmonary dysplasia (BPD) [1,2].To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017; 10:CD001146.
- Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017; 10:CD001145.
- Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004; 114:1649.
- Baud O, Maury L, Lebail F, et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet 2016; 387:1827.
- Baud O, Trousson C, Biran V, et al. Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age. JAMA 2017; 317:1329.
- Marlow N. Reevaluating Postnatal Steroids for Extremely Preterm Infants to Prevent Lung Disease. JAMA 2017; 317:1317.
- Stark AR, Carlo WA, Tyson JE, et al. Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001; 344:95.
- O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999; 104:15.
- Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005; 115:655.
- Doyle L, Davis P. Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function. J Paediatr Child Health 2000; 36:101.
- Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001; 1:1.
- Doyle LW, Halliday HL, Ehrenkranz RA, et al. An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. J Pediatr 2014; 165:1258.
- Parikh NA, Lasky RE, Kennedy KA, et al. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics 2007; 119:265.
- Watterberg KL, American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement--postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010; 126:800.
- Yoder BA, Harrison M, Clark RH. Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics 2009; 124:673.
- Kobaly K, Schluchter M, Minich N, et al. Outcomes of extremely low birth weight (<1 kg) and extremely low gestational age (<28 weeks) infants with bronchopulmonary dysplasia: effects of practice changes in 2000 to 2003. Pediatrics 2008; 121:73.
- Walsh MC, Yao Q, Horbar JD, et al. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006; 118:e1328.
- Shinwell ES, Lerner-Geva L, Lusky A, Reichman B. Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2007; 92:F30.
- Cheong JL, Anderson P, Roberts G, et al. Postnatal corticosteroids and neurodevelopmental outcomes in extremely low birthweight or extremely preterm infants: 15-year experience in Victoria, Australia. Arch Dis Child Fetal Neonatal Ed 2013; 98:F32.
- Horbar JD, Carpenter JH, Badger GJ, et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. Pediatrics 2012; 129:1019.
- Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126:443.
- Kothadia JM, O'Shea TM, Roberts D, et al. Randomized placebo-controlled trial of a 42-Day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Pediatrics 1999; 104:22.
- Doyle LW, Davis PG, Morley CJ, et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006; 117:75.
- Wilson-Costello D, Walsh MC, Langer JC, et al. Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants. Pediatrics 2009; 123:e430.
- Wood NS, Costeloe K, Gibson AT, et al. The EPICure study: associations and antecedents of neurological and developmental disability at 30 months of age following extremely preterm birth. Arch Dis Child Fetal Neonatal Ed 2005; 90:F134.
- Needelman H, Evans M, Roberts H, et al. Effects of postnatal dexamethasone exposure on the developmental outcome of premature infants. J Child Neurol 2008; 23:421.
- Cheong JL, Burnett AC, Lee KJ, et al. Association between postnatal dexamethasone for treatment of bronchopulmonary dysplasia and brain volumes at adolescence in infants born very preterm. J Pediatr 2014; 164:737.
- Onland W, De Jaegere AP, Offringa M, van Kaam AH. Effects of higher versus lower dexamethasone doses on pulmonary and neurodevelopmental sequelae in preterm infants at risk for chronic lung disease: a meta-analysis. Pediatrics 2008; 122:92.
- Lodygensky GA, Rademaker K, Zimine S, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 2005; 116:1.
- Rademaker KJ, Uiterwaal CS, Groenendaal F, et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr 2007; 150:351.
- Watterberg KL, Shaffer ML, Mishefske MJ, et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007; 120:40.
- Needelman H, Hoskoppal A, Roberts H, et al. The effect of hydrocortisone on neurodevelopmental outcome in premature infants less than 29 weeks' gestation. J Child Neurol 2010; 25:448.
- Parikh NA, Kennedy KA, Lasky RE, et al. Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes. J Pediatr 2013; 162:685.
- Kersbergen KJ, de Vries LS, van Kooij BJ, et al. Hydrocortisone treatment for bronchopulmonary dysplasia and brain volumes in preterm infants. J Pediatr 2013; 163:666.
- Patra K, Greene MM, Silvestri JM. Neurodevelopmental impact of hydrocortisone exposure in extremely low birth weight infants: outcomes at 1 and 2 years. J Perinatol 2015; 35:77.
- Peltoniemi OM, Lano A, Yliherva A, et al. Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Acta Paediatr 2016; 105:159.
- Watterberg KL. Postnatal steroids for bronchopulmonary dysplasia: where are we now? J Pediatr 2007; 150:327.
- van der Heide-Jalving M, Kamphuis PJ, van der Laan MJ, et al. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? Acta Paediatr 2003; 92:827.
- Karemaker R, Kavelaars A, ter Wolbeek M, et al. Neonatal dexamethasone treatment for chronic lung disease of prematurity alters the hypothalamus-pituitary-adrenal axis and immune system activity at school age. Pediatrics 2008; 121:e870.
- Hassan AH, von Rosenstiel P, Patchev VK, et al. Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone. Exp Neurol 1996; 140:43.
- De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998; 19:269.
- McEwen BS. The brain is an important target of adrenal steroid actions. A comparison of synthetic and natural steroids. Ann N Y Acad Sci 1997; 823:201.
- Heine VM, Rowitch DH. Hedgehog signaling has a protective effect in glucocorticoid-induced mouse neonatal brain injury through an 11betaHSD2-dependent mechanism. J Clin Invest 2009; 119:267.
- Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010; 98:111.
- Bose CL, Laughon MM. Corticosteroids and chronic lung disease: time for another randomized, controlled trial? Pediatrics 2005; 115:794.
- Bassler D, Plavka R, Shinwell ES, et al. Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. N Engl J Med 2015; 373:1497.
- Shah VS, Ohlsson A, Halliday HL, Dunn M. Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. Cochrane Database Syst Rev 2017; 1:CD001969.
- Onland W, Offringa M, van Kaam A. Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017; 8:CD002311.
- Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2017; 10:CD002058.
- Beresford MW, Primhak R, Subhedar NV, Shaw NJ. Randomised double blind placebo controlled trial of inhaled fluticasone propionate in infants with chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2002; 87:F62.
- Dugas MA, Nguyen D, Frenette L, et al. Fluticasone inhalation in moderate cases of bronchopulmonary dysplasia. Pediatrics 2005; 115:e566.
- Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 2017; 10:CD002057.
- SYSTEMIC STEROIDS
- - Hydrocortisone
- Short-term adverse effects
- Long-term outcome
- - Reduced steroid use and BPD
- Risk/benefit of systemic therapy
- - Are there patients who would benefit from steroid therapy?
- Corticosteroid dose
- Hydrocortisone versus dexamethasone
- Unanswered questions
- AAP guidelines
- OUR APPROACH
- INHALED CORTICOSTEROID
- Prevention of BPD
- Treatment of BPD
- Our approach to inhaled steroids
- SUMMARY AND RECOMMENDATIONS